A maintenance trial and progression
A fictional patient with a pathogenic germline BRCA variant has metastatic pancreatic cancer and has progressed during the preceding platinum-containing treatment. A trainee finds a maintenance trial involving a biomarker-matched population and assumes that the genetic match alone makes its result directly applicable. The abstract specifies that enrolled patients had not progressed through the qualifying initial platinum period. No separate evidence for the proposed postprogression use is supplied. The supervising clinician asks the trainee to distinguish biological rationale from the exact disease state and eligibility of the study. The case does not require choosing a complete next-line regimen or making a current national reimbursement claim.
1. Why is the direct maintenance inference unsupported?
Read the worked answer
The qualifying trial required disease control before maintenance. Progression through that treatment is a different clinical state despite the same inherited biomarker.
2. What should be compared before transferring the result?
Read the worked answer
Compare disease state, prior therapy, response, actual eligibility, endpoints and alternative evidence, rather than treat a molecular match as sufficient.